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New management issues for commonly occurring psychiatric syndromes are discussed in this editorial.
Cannabis use and schizophrenia
We know that there is a relationship between 
cannabis use and schizophrenia. The pre-
cise nature of this relationship remains un-
clear. In a recent review, Smit et al 1 looked at 
five population based, longitudinal studies on 
the relationship between cannabis use and 
problems ranging from psychotic symptoms 
to hospitalisation with a confirmed diagnosis 
of schizophrenia. They concluded that the re-
viewed studies highlight six key elements:1
­ Cannabis use roughly doubles the risk of 
developing schizophrenia.
­ Many young people expose themselves to 
this risk.
­ The risk increases when more cannabis is 
used.
­ There is also an increased risk in ‘vulnera-
ble’ people.
­ Vulnerability may be widespread, but diffi-
cult to recognise.
­ Even when the risk is numerically small, in 
clinical terms it is serious.
In a recent South African study on cannabis 
and other variables affecting age at onset in a 
schizophrenia founder population, the follow-
ing conclusions were reached:2
­ The percentage of male and female Afri-
kaner schizophrenia subjects who used/
abused cannabis was higher than the life-
time rates for males and females in a rep-
resentative sample of grade 11 students in 
South Africa (SA).3
­ More emphasis should be placed on the 
psycho-education and rehabilitation of 
young vulnerable individuals with schizo-
phrenia who use and abuse cannabis.
­ Early deviant behaviour was the most im-
portant factor determining age of criteria 
onset and, in male patients with schizophre-
nia, it may be an endophenotypic marker.
­ The interactive effect of gender and can-
nabis use was also significant in explain-
ing the age of criteria onset in males. Yet 
is seems that when cannabis is used, the 
effect of early deviant behaviour becomes 
less important in determining the age of cri-
teria onset.
­ In our search for more sophisticated endo-
phenotypes to aid the identification of sus-
ceptibility and modifying genes, early devi-
ant behaviour, male gender and cannabis 
use/abuse in interaction may be factors to 
consider in future research.
It should be asked whether enough is be-
ing done in SA in terms of prevention mea-
sures regarding cannabis use, as it has a di-
rect effect on one of the serious psychiatric ill-
nesses. I am in full agreement with Smith et al 
1that wisdom will be required to formulate a 
health education message that will have the 
desired effect. Warnings may not help and 
may even be counter-productive, but ignor-
ing the message contained in the five studies 
is not an option.
Metabolic Effects of Second Generation 
Antipsychotics
Most of the second generation antipsychot-
ics have been available in SA for more than 
5 years.  As we gained more experience in 
the use of these drugs, we also realised that 
some of our best medications are associat-
ed with the greatest metabolic side-effects.4 
We face the dilemma of seeing improvement 
in psychotic symptoms accompanied by sig-
nificant weight gain, lipid disturbance and, 
occasionally, emergent diabetes. In a re-
cent guest editorial, Cohn5 posed the follow-
ing questions:
­ Our primary goal is to treat psychiatric ill-
ness, but do we need to accept the side-
effects of treatment as inevitable and un-
avoidable?
­ How do we understand and manage meta-
bolic risk when we treat psychosis?
­ Are we truly keeping in mind the long-term 
interest of our patients?
In his review on pharmacological and non-
pharmacological strategies for the preven-
tion of weight gain and metabolic distur-
bance in patients treated with antipsychotic 
medications, Faulkner et al 6 come to the con-
clusion that, although difficult, the prevention 
of weight gain and the promotion of weight 
loss are possible for individuals treated with 
antipsychotic medications. Further research, 
including diabetes prevention studies, is re-
quired. They suggest a pathway for the man-
agement of weight gain and emerging meta-
bolic disturbance. 6  The clinical implications 
of their review emphasise the following:6
­ Psychiatrists have an important role to play 
in managing the weight gain and metabolic 
disturbance than can accompany antipsy-
chotic treatment.
­ Weight management and lifestyle advice 
should be offered to all patients.
­ There is insufficient evidence to support the 
general use of pharmacological interven-
tions for weight management.
Children and the use of ADHD drugs
The Food and Drug Administration (FDA) 
Drug Safety and Risk Management Adviso-
ry Committee recently held meetings where 
they voiced their support for the use of a new 
black box warning in the labelling of pharma-
cotherapies for ADHD that would list sudden 
death and cardiovascular events as pos-
sible sequelae from their use.7 This made 
media and internet-informed parents ques-
tion whether they should keep their child on 
ADHD drugs.
In an interesting and fact finding editorial in 
the June 2006 issue of The Journal of Clinical 
Psychopharmacology,8 Shader and Oester-
held made the following observations:
− There is little question about the efficacy of 
these agents for ADHD symptoms in most 
appropriately diagnosed children.
− There is a need of appropriate diagnosis 
and careful observation of children and ado-
lescents before and after they are placed on 
any medication.
− Drugs for ADHD are probably over pre-
scribed to some populations.
Furthermore, they do not challenge the notion 
that sympathomimetic drugs at certain dos-
es and in certain children and adolescents 
may raise blood pressure and heart rate. It 
seems probable that the use of sympathomi-
metic agents could be a contributing risk fac-
tor for sudden death in some predisposed 
children and adolescents. They had an issue 
with overgeneralisations, class labelling con-
cepts, and the lumping of all ADHD drugs to-
gether. They feel stricter warnings are going 
to have significant consequences for the use 
of these drugs. It will be more difficult to con-
vince parents to allow children with ADHD to 
use these agents. Other drugs that are not 
as effective and which have their own CVS 
side-effects may be used. They feel further 
research is urgently needed and that major 
public policy changes must be based on sol-
id evidence. Hopefully, this information will 
help doctors to answer parents’ questions 
and in making informed decisions.
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